Endeavor Health, GoPath researchers develop new genetic risk test for aggressive prostate cancer
Test is first of its kind to be made clinically available; Results of studies published in Prostate Cancer and Prostatic Disease, The Prostate journals EVANSTON, Ill., Nov. 2, 2026 /PRNewswire/ -- Researchers at Endeavor Health and GoPath Diagnostics have developed a new genetic test that...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 96 stories mentioning NOV, the earliest published 8 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.